Alan B. Lancz & Associates’s Cerence CRNC Stock Holding History

Alan B. Lancz & Associates’s Portfolio CRNC Stock Details CRNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-2,886	Closed	-$221K	–	150
2021 Q4	$221K	Buy	+2,886	New	+$254K	0.19%	132

Other funds holding CRNC

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VVP

Vulcan Value Partners Birmingham, Alabama $3.77B AUM 9.63% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GKIM

GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VBA

Van Berkom & Associates Montreal, Quebec, Canada $3.08B AUM 12.07% 1-Year Est. Return

Alan B. Lancz & Associates's CRNC Position: Q1 2022 in Review

Alan B. Lancz & Associates sold out of Cerence (CRNC) in Q1 2022, closing a stake of 2,886 shares — an estimated $221K sold.

Alan B. Lancz & Associates first reported a position in CRNC in Q4 2021 and held it in 1 quarter. The position peaked at $221K in Q4 2021. 286 funds tracked by Wall St. Rank hold CRNC as of Q1 2022.

Alan B. Lancz & Associates reported no remaining Cerence position as of Q1 2022 after selling out during the quarter.
Alan B. Lancz & Associates sold 2,886 Cerence shares in Q1 2022, an estimated $221K.
Alan B. Lancz & Associates first reported a position in Cerence in Q4 2021 and held it in 1 quarter.
Alan B. Lancz & Associates's Cerence position peaked at $221K in Q4 2021.
286 funds tracked by Wall St. Rank held Cerence as of Q1 2022.

Based on Alan B. Lancz & Associates's 13F filing for Q1 2022, filed 12 May 2022.